NDC product
Clindamycin phosphate
NDC 0338-3612 · Baxter Healthcare Company
Key facts
| Product NDC | 0338-3612 |
|---|---|
| Proprietary name | Clindamycin phosphate |
| Nonproprietary name | Clindamycin phosphate |
| Substances | CLINDAMYCIN PHOSPHATE |
| Dosage form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Labeler | Baxter Healthcare Company |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA208084 |
| Pharmacologic classes | Decreased Sebaceous Gland Activity [PE], Lincosamide Antibacterial [EPC], Lincosamides [CS], Neuromuscular Blockade [PE] |
| Marketing start | Jun 28, 2017 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: